Product Datasheet
|
|
|
Product Description |
|
Product: |
COVID-19 Convalescent Patient Antibody, IgG Fraction |
Catalog Number: |
COVID-GF |
Product Page: |
https://www.mol-innov.com/products/IHUCOVIGGGFLY50UG |
Description: |
SARS-CoV-2 is the novel coronavirus that causes CoronaVirus Disease 2019 (COVID-19). This IgG fraction is purified by immobilized Protein A from pooled sera collected from convalescent COVID-19 patients. Serum was collected at least two weeks post symptom development from patients with positive COVID-19 PCR and serology tests. This antibody preparation is strongly positive in the Molecular Innovations SARS-CoV-2 IgG Seroconversion ELISA Kit and can be useful as a positive control or calibrator in a variety of serological assays. Add PBS to desired volume, aliquot and freeze unused portion. |
Recommended Storage: |
SAMPLE |
Minimum Shelf Life: |
276.50 |
Source: |
Lyophilized |
Molecular Weight: |
Antibodies |
Extinction Coefficient: |
160,000 |
Antigen: |
-20 C |
Target: |
Lyophilized powder
|
Target Molecular Weight: |
COVID-19 |
Host: |
416.5 |
Clonality: |
30 |
Isotype: |
Human serum |
Clone: |
s |
Applications: |
Cold pack |
Cross-reactivity: |
5 years from delivery
|
|
Sample Characteristics |
|
Lot Number: |
COVID-GF-IHUCOVIGGGFLY100UG |
Aliquot: |
1 x Human IgG from Covid-19 Convalescent Plasma Fractionated Purified Lyophilized 100ug |
Concentration: |
395 |
Volume: |
595 |
Titer: |
0.05M Sodium Phosphate; 0.1M NaCl; 1mM EDTA; pH 6.6
|
Buffer: |
SAMPLE |
Form: |
0.05 mg |
Preservative: |
0.005 ml before lyophilization |
|
Optimal experimental conditions and working dilutions must be determined by the end user. Sample concentration and volume are for example purposes only and do not necessarily represent the product that will be received. Please contact us for a current lot-specific product datasheet. |
|
For in vitro laboratory use only |
|
Molecular Innovations, Inc. - 46430 Peary Court, Novi, MI 48377, USA Tel: (888) 557-5055 - Fax: (248) 896-0148 - info@mol-innov.com |